| |
•
•
•
|
| |
Proud sponsor of:
|
|
| |
| June 2, 2010 | Alexion to Present at Investor Conferences | | Cheshire, CT, June 2, 2010 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences:
Mr. Vikas Sinha, Chief Financial Officer of Alexion, will present at the 9th Annual Needham Healthcare Conference in New York City on Wednesday, June 9th at 11:20 a.m., Eastern Time.
Dr. Leonard Bell, Chief Executive Officer of Alexion, will present at the Jefferies 2010 Global Life Sciences Conference in New York City on Thursday, June 10th at 8:00 a.m., Eastern Time.
An audio webcast of each presentation will be available live. You can access the webcasts at: www.alexionpharma.com. An archived version of the remarks will also be available through the Company’s web site for a limited time following the conference.
Contacts:
Alexion Pharmaceuticals, Inc.
Irving Adler
Sr. Director, Corporate
Communications
(203) 271-8210
Makovsky + Company
Mark Marmur (Media)
(212) 508-9670
Rx Communications
Rhonda Chiger (Investors)
(917) 322-2569
| | June 3, 2010 | ThromboGenics to Present at the Jefferies 2010 Global Life Sciences Conference in New York on 10 June | | Leuven, Belgium – 3 June 2010 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that Patrik De Haes, Chief Executive Officer of ThromboGenics will present an overview of the Company’s strategy and key development programs at the Jefferies 2010 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, U.S. on 10 June 2010 at 9.30am EDT.
The Company’s presentation can be accessed via www.thrombogenics.com
---------
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead product microplasmin has completed its first Phase III clinical trial for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase I for cancer in partnership with Roche.
ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.
Dr. Patrik De Haes, CEO
Tel: + 32 16 75 13 10
patrik.dehaes@thrombogenics.com
Chris Buyse, CFO
Tel: + 32 16 75 13 10
chris.buyse@thrombogenics.com
Citigate Dewe Rogerson
Amber Bielecka/ David Dible/ Nina Enegren
Tel: +44 (0) 207 638 95 71
amber.bielecka@citigatedr.co.uk
Rhonda Chiger
US Investors
917-322-2569
rchiger@rxir.com | | June 8, 2010 | Alexion to Present at Investor Conferences | | Cheshire, CT, June 8, 2010 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences:
Mr. Vikas Sinha, Chief Financial Officer of Alexion, will present at the 30th Annual William Blair & Company Growth Stock Conference in Chicago on Tuesday, June 15th at 2:10 p.m., local time (3:10 p.m., Eastern Time).
Dr. Leonard Bell, Chief Executive Officer of Alexion, will present at the Goldman Sachs 31st Annual Global Healthcare Conference in Los Angeles on Wednesday, June 16th at 2:00 p.m., local time (5:00 p.m. Eastern Time).
An audio webcast of each presentation will be available live. You can access the webcasts at: www.alexionpharma.com. An archived version of the remarks will also be available through the Company’s web site for a limited time following the conference.
Alexion Pharmaceuticals, Inc.
Irving Adler
Sr. Director, Corporate
Communications
(203) 271-8210
Makovsky + Company
Mark Marmur (Media)
(212) 508-9670
Rx Communications
Rhonda Chiger (Investors)
(917) 322-2569
|
|
|
|
|
|
